Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288613 · ClinicalTrials.gov registry record
FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study
A clinical trial of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis, sponsored by NxStage Medical.
- Completed
- Registry status
- 501
- Enrollment target
- 20
- Study locations
NCT00288613: Completed study of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis, sponsored by NxStage Medical.
NCT00288613 is a study of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis that has completed, run by NxStage Medical. The registered enrollment target is 501 participants, above the 310-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00288613, a study of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis, has completed, sponsored by NxStage Medical.
- COMPLETED
- Registry status
- 501 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose The purpose of this study is to compare the economical impact and clinical parameters of short daily hemodialysis using the NxStage® System One hemodialysis device with thrice-weekly conventional in-center dialysis using a matched cohort from the US Renal Data System (USRDS) database.
Primary Outcome
To compare the all-cause hospitalizations reported in days per patient year on daily hemodialysis using NxStage System One hemodialysis device to thrice-weekly conventional in-center dialysis using a matched cohort from the US Renal Data System (USRDS) database
Conditions Studied
Study Locations (20)
California
- Renal Advantage (RAI) - Garden Grove
- Satellite Healthcare/Wellbound - Mountain View
- Renal Advantage (RAI) - Oakland
- Kidney Center, Inc. - Simi Valley
Michigan
- Great Lakes Renal Network - Alma
- Henry Ford Health System - Detroit
- Munson Dialysis Center - Traverse City
Arkansas
- Fort Smith Regional Dialysis Center - Fort Smith
- Arkansas Nephrology Research Associates - Hot Springs
Illinois
- Circle Medical Management - Chicago
- Affiliated Home Dialysis - Glen Ellyn
Indiana
- Indiana University Medical Center - Indianapolis
- Nephrology, Inc. - Mishawaka
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Metabolism Associates - New Haven CAPD - New Haven
Florida
- RAI Palm Harbor, Outcomes Research Int'l - Hudson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2006-01 |
| Est. Completion | 2013-11 |
What the finished NCT00288613 record still lists
NCT00288613 is an observational study that tracks outcomes without assigning an intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 310-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (62% higher).
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 0 interventions.
NCT00288613 names 20 study sites across 12 states, led by California, Michigan, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00288613 about?
NCT00288613 is a clinical study titled "FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study". Purpose The purpose of this study is to compare the economical impact and clinical parameters of short daily hemodialysis using the NxStage® System One hemodialysis device with thrice-weekly conventional in-center dialysis using a matched cohort from the US Renal Data System (USRDS) database.
What is the current status of trial NCT00288613?
This trial is currently completed. The enrollment target is 501 participants. The study started on 2006-01. Estimated completion is 2013-11.
What conditions does trial NCT00288613 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, End Stage Renal Disease, Requiring Dialysis.
Who is sponsoring clinical trial NCT00288613?
This trial is sponsored by NxStage Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00288613 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00288613's enrollment target sits among peer trials
501 5th of 23 higher than 19 of 23 other Kidney Failure, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Failure, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
International (Pediatric) Peritoneal Biobank
RECRUITING
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Kidney Function in Sickle Cell Anemia
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia